Skip to main content
Sofdra healthcare professionals homepage

Designed for
sweat like this

Sofdra is the only topical treatment that contains a novel molecule purposefully designed for primary axillary hyperhidrosis1,2

Prescribe Sofdra exclusively through SendRx
—commercially insured patients pay $0*

Purposefully developed

A novel topical agent created to target M3 acetylcholine receptors that signal excessive sweating in axillary glands.1-3

See Sofdra
in action

Designed for convenience

Comes with a proprietary metered-dose pump and convenient applicator to limit unwanted drug contact.4

Discover application
and dosing

Available for $0*

Exclusively available through SendRx Pharmacy Network—$0 for commercially insured patients

*Terms and Conditions apply.

Prescribe only
through SendRx
Primary axillary hyperhidrosis is a common dermatological condition—yet patients still struggle to stay dry.5-7
See why

Indication

Sofdra™ (sofpironium) topical gel, 12.45% is an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications

Sofdra is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of Sofdra (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjögren’s syndrome).

Warnings & Precautions

Urinary retention

Use Sofdra with caution in patients with a history or presence of documented urinary retention. Patients should discontinue use immediately and consult a healthcare provider should any signs or symptoms of urinary retention develop (e.g., difficulty passing urine, distended bladder).

Control of Body Temperature

In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs, including Sofdra. Patients should avoid using Sofdra if not sweating when in hot or very warm environmental temperatures.

Operating Machinery or an Automobile

Transient blurred vision may occur with Sofdra. If blurred vision occurs, discontinue use and avoid engaging in activities that require clear vision (e.g., operating a motor vehicle or machinery, performing hazardous work) until the symptoms have resolved.

Adverse Reactions

The most common adverse reactions (≥2%) are dry mouth, vision blurred, mydriasis, and urinary retention. The most common local skin reactions (≥2%) are pain, erythema, dermatitis, pruritus, irritation, and exfoliation.

Drug Interactions

Avoid coadministration of Sofdra with other anticholinergic medications (due to risk of increase in anticholinergic adverse effects) and drugs that are strong inhibitors of CYP2D6.

Please see full Prescribing Information.

References: 1. Sofdra™ (sofpironium) topical gel, 12.45%. Prescribing Information. Wayne, PA: Botanix SB Inc. 2. Fujimoto T, Abe Y, Igarashi M, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(9):1149–1161 doi:10.1111/1346-8138.15927 3. Gregoriou S, Tsiogka A, Kontochristopoulos G, Offidani A, Campanati A. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis. Expert Opin Investig Drugs. 2022; 31(1):1,15–21. doi:10.1080/13543784.2022.2017880 4. Sofdra™ (sofpironium) topical gel, 12.45%. Instructions for Use. Wayne, PA: Botanix SB Inc. 5. Doolittle J, Walker P, et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743–749 doi:10.1007/s00403-016-1697-9 6. Hamm H, Naumann M, Kowalski J, et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353 doi:10.1159/000092285 7. Parashar K, Adlam T, Potts G. The impact of hyperhidrosis on quality of life: a review of the literature. Am J Clin Dermatol. 2023;24(2):187–198 doi:10.1007/s40257-022-00743-7
This site is intended for US healthcare professionals only.
Sofdra is a trademark of Botanix SB Inc.

© 2025 Botanix SB Inc. All rights reserved. PRO‑1063‑SOF‑v1 01/2025